Zai Lab

Zai Lab FCF/Debt

The Free Cash Flow to Debt Ratio of Zai Lab (9688.HK) as of Nov 2, 2026 is -70.96 %. In the previous year, Free Cash Flow to Debt Ratio was -22.96 % — a change of 209.02% (lower).

FCF/Debt

-70.96 %

YoY

209.02%

Last updated:

Free Cash Flow to Debt Ratio of Zai Lab is 2025 -70.96 % . Free Cash Flow to Debt Ratio of Zai Lab was 2024 -22.96 % . It decreases by 209.02% lower compared to the previous year.

The Zai Lab FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-2,955.45 USD
Jan 1, 2019
-947.07 USD
Jan 1, 2020
-1,219.08 USD
Jan 1, 2021
-3,656.24 USD
Jan 1, 2022
-1,925.30 USD
Jan 1, 2023
-1,364.06 USD
Jan 1, 2024
-22.96 USD
Jan 1, 2025
-70.96 USD
The Zai Lab FCF/Debt history
YEARFCF/DebtYoY
-70.96 %+209.02%
-22.96 %-98.32%
-1,364.06 %-29.15%
-1,925.30 %-47.34%
-3,656.24 %+199.92%
-1,219.08 %+28.72%
-947.07 %-67.96%
-2,955.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd. focuses on discovering, developing, and commercializing proprietary therapeutics for unmet medical needs in China, particularly in oncology, autoimmune, and infectious diseases. The company's pipeline includes drug candidates such as Niraparib (ZL-2306), ZL-2103, and ZL-1101, which are in various stages from discovery to late-stage clinical programs. Its products target large patient segments requiring innovative treatments within the Chinese healthcare market. The firm's revenue comes from the commercialization of its proprietary drug candidates, which are developed through internal research and strategic partnerships. Zai Lab Ltd. serves the Chinese biopharmaceutical market, targeting healthcare providers, hospitals, and patients seeking advanced therapies for conditions like cancer and autoimmune disorders. The company leverages its pipeline to generate sales through pharmaceutical distribution channels in China. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

Free Cash Flow to Debt Ratio of Zai Lab is -70.96 % in 2025.

Free Cash Flow to Debt Ratio of Zai Lab changed from -22.96 % to -70.96 %, representing a 209.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Zai Lab since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Zai Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Zai Lab

All Key Metrics — Zai Lab